PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Leva Clinic fundraises £3m for UK’s first digital chronic pain platform

Funding will be used to broaden partnerships with the NHS and improve patient experience.

Leva has announced that it has secured £3m ($3.5m) of funding from Óskare Capital and 2420 Partners. A significant investment will be used to scale the delivery of digital solutions for chronic pain patients. Crucially, it will also accelerate innovation in medical cannabis therapeutics.

A quarter of adults in the UK are living with a pain condition that has lasted over three months. Chronic pain has often been dubbed a ‘silent epidemic’, while pain costs the UK economy significantly more than cancer and heart disease, and almost as much as diabetes and obesity costs.

Currently, a lack of personalised treatment options, and difficulties in accessing clinical support, currently prevent millions of adults from addressing pain without taking opioids – the risks of which have been well-publicised.

Leva Clinic remains the UK’s first online facility for patients living with chronic pain. Regulated by the Care Quality Commission, the clinic delivers a range of digital services to help patients manage their conditions. These include physiotherapist support, pain management techniques, doctor-led medication reviews, and prescription provision.

Justin Hartfield, who founded the global cannabis technology platform ‘Weedmaps’ in 2008, made his investment via his private investment office 2420 Partners.

He commented: “Our investment in Leva is perfectly aligned with our goal to support emerging businesses in the pain management space globally. Leva is on the path to being a market leader in delivering innovative pain management solutions by industry-leading pain experts in the UK. We are excited to partner with the company in its next chapter of growth.”

Leva is a founding member of Project Twenty21 – the largest observational medical cannabis study in the UK.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026